Advice
in the absence of a submission from the holder of the marketing authorisation
bendamustine (Levact ®) is not recommended for use within NHS Scotland.
Indication under review: Indolent non-Hodgkin's lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice38KB (PDF)
Medicine details
- Medicine name:
- bendamustine (Levact)
- SMC ID:
- 701/11
- Indication:
- Indolent non-Hodgkin's lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 April 2011